Iwona Welian-Polus

Iwona Welian-Polus

Auto-generated profile, based on publicly available information

Iwona Welian-Polus

Medical University of Lublin

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 February 2024 in Journal of Pre-Clinical and Clinical Research
Verified
Journal Article
Open access
SUSylwia Marta Urbańska
Sylwia Marta Urbańska
MLMichał Leśniewski
Michał Leśniewski
IWIwona Welian-Polus
Iwona Welian-Polus
AWAleksandra Witas
Aleksandra Witas
KSKlaudia Szukała
Klaudia Szukała
MCMagdalena Chroscinska-Krawczyk
Magdalena Chroscinska-Krawczyk
Introduction and objective: Epilepsy is one of the most commonly diagnosed neurological aberrations. Epileptic seizures are the main symptoms of the condition. Reducing the seizures is the main objective of the treatment. The aim of the review is to summarise current knowledge on diagnosis and...

24 April 2023 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
IWIwona Welian
Iwona Welian
KGKarolina Gendek
Karolina Gendek
IJIlona Jastrzębska
Ilona Jastrzębska
KMKarolina Maliszewska
Karolina Maliszewska
MCMagdalena Chroscinska-Krawczyk
Magdalena Chroscinska-Krawczyk
Spinal muscular atrophy (SMA) is a genetically inherited disease whose symptoms appear in children at a fairly early age. The main cause of the disease is a mutation of the SMN1 gene, which causes the lack of production of SMN This results in the disappearance of motoneurons, which consequently leads to the disappearance of the patient's ability to move and his death. An important element of coping with the disease is its early detection in newborn screening, because the earlier we start the drug, the greater the chance that the patient will maintain motor efficiency. The article describes treatment options for children in Poland, i. e. the use of such drugs as Nusinersen, which increases the amount of SMN protein, gene therapy Onasemnogen aeparvovec, which increases the amount of SMN gene, Ridisplam, which increases the amount of SMN protein, and salbutamol, which helps patients to breathe. The article also provides information about new drug therapies for the treatment of SMA and the stage of clinical trials at which they are currently being developed. It is important to look for new solutions in the treatment of SMA. Objective: To familiarize the readers of the article with the problems of SMA treatment in Poland, as well as to broaden their knowledge of new available drugs for the treatment of this disease.

14 May 2024 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
IWIwona Welian-Polus
Iwona Welian-Polus
BMBartosz Mazur
Bartosz Mazur
MBMichał Bielak
Michał Bielak
MMMagdalena Mazur
Magdalena Mazur
ERElżbieta Rypulak
Elżbieta Rypulak
KTKamila Turek
Kamila Turek
Introduction: Duchenne muscular dystrophy is a genetic X-linked recessive disorder. This condition is characterized by progressive loss of muscle tissue. Thus, it results in deterioration and inability to perform basic motor skills such as independent movement or breathing. Due to progressive muscle weakness, patients with advanced stages of DMD require mechanical ventilation, feeding, and rehabilitation. Furthermore, alterations in cardiac muscle lead to cardiomyopathy. Despite advanced supportive treatment, DMD is a fatal disease. Purpose: The aim of the paper is to present, using a case study description, the current standards of treatment for patients with Duchenne muscular dystrophy as well as the current state of knowledge and new discoveries regarding this medical condition. Material and methods The patient's medical records were analyzed and available literature in PubMed was reviewed to write this article using the keywords: „Duchenne muscular dystrophy”; „cardiomyopathy”; „mechanical ventilation”; „gene therapy”; Conclusions Early detection of respiratory and circulatory insufficiency improves the patient's quality of life. Many patients with an advanced stage of Duchenne muscular dystrophy need specialized treatment, for example, in the intensive care unit. Therefore there is an urgent need for new treatment methods, such as gene therapies, which can slow down or break the course of the disease. New discoveries and the implementation of new treatment standards can enhance the quality of life for patients and extend their lifespans.

24 February 2024 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
MLMichał Leśniewski
Michał Leśniewski
IWIwona Welian-Polus
Iwona Welian-Polus
IOIzabela Oleksak
Izabela Oleksak
KMKarolina Maliszewska
Karolina Maliszewska
Neurofibromatosis is one of the most common genetic diseases. It is inherited in an autosomal dominant manner. It is divided into two genetically distinct subtypes, characterised by multiple skin lesions and tumours of the peripheral and central nervous system. Neurofibromatosis type 1, or Recklinghausen's disease, is the most common phakomatosis. The disease is genetically determined by a mutation of the neurofibromin- 1 gene on chromosome 17. Neurofibromatosis type 2 accounts for 3% of all cases. The disease is genetically determined - caused by a mutation of the neurofibromin-2 gene on chromosome 22. The diagnostic and therapeutic process of neurofibromatosis is a major challenge for clinicians. Given the complexity of the problem, we have reviewed the literature on the diagnostic and therapeutic possibilities of the disease.

22 December 2023 in Journal of Pre-Clinical and Clinical Research
Verified
Journal Article
Open access
IWIwona Welian-Polus
Iwona Welian-Polus
MKMarcelina Kurek
Marcelina Kurek
MBMichał Bielak
Michał Bielak
AZAleksandra Ziółkiewicz
Aleksandra Ziółkiewicz
KSKlaudia Szukała
Klaudia Szukała
MCMagdalena Chroscinska-Krawczyk
Magdalena Chroscinska-Krawczyk
Introduction and objective: Civilization diseases are widespread in the adult population. However, their occurrence has been increasing recently in children. The aim of this review is to introduce the most common diseases and present their diagnosis and treatment methods. Review methods: The...

7 February 2024 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
IOIzabela Oleksak
Izabela Oleksak
MLMichał Leśniewski
Michał Leśniewski
IWIwona Welian-Polus
Iwona Welian-Polus
KMKarolina Maliszewska
Karolina Maliszewska
JZJoanna Ziółkowska
Joanna Ziółkowska
Introduction and purpose: Among neurodegenerative disorders, Alzheimer's disease (AD) and Parkinson's disease (PD) are the most prevalent. It has been observed recently that alterations in the gut microbiota are associated with the onset of neurodegenerative disorders. This research aims to estimate the pathomechanisms and disease courses associated with the gut microbiota that lead to AD and PD development. Material and methods The following review was based on articles from the PubMed and Google Scholar databases. Key search terms included Alzheimer’s disease; Parkinson’s disease; gut microbiota; neurodegenerative diseases. State of knowledge The advancement of neurodegenerative processes is linked to the varying progressive course of both disorders. There are numerous likely reasons that connect the development of AD and PD and the gut microbiome. These include the hypotheses on inflammation, the decrease in the quantity of bacteria that produce short-chain fatty acids, and hygiene. The researchers' suggested treatment plans for the two illnesses are comparable. Conclusions A major influence on the development of neurodegenerative disorders is the gut microbiome. To clarify the precise connections between the gut microbiota and the development of AD and PD, further thorough research is required. More human research is required. Furthermore, it's possible that early interventions, such switching to a Mediterranean diet, are anticipated to lower the risk of AD or PD.